InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
stocktrader001 Free
06/27/13 4:16 PM
profile icon
mlkrborn Free
02/02/13 11:41 AM
profile icon
Norm Free
02/02/13 6:10 AM
profile icon
mlkrborn Free
01/16/13 11:03 AM
profile icon
Norm Free
12/10/12 12:53 PM
profile icon
Norm Free
12/07/12 1:10 PM
profile icon
PoemStone Deceased
10/02/12 9:04 PM
profile icon
Norm Free
09/15/12 8:33 PM
profile icon
Norm Free
09/06/12 8:39 PM
profile icon
Norm Free
09/06/12 7:49 PM

Hyperion Therapeutics, Inc. (HPTX) RSS Feed

Followers
3
Posters
5
Posts (Today)
0
Posts (Total)
12
Created
09/06/12
Type
Free
Moderators



Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.

Hyperion is currently developing Ravicti™ (glycerol phenylbutyrate), formerly known as HPN-100, for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd's worldwide rights to BUPHENYL® and, subject to certain conditions, AMMONUL®.

Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products.

{C}
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
HPTX Latest News
  • No Recent News Available for this company!
New Post